Kintara Therapeutics

Kineta, Inc. and potential partner TuHura Biosciences revealed on 19 August that enrollment is resuming in the Phase I portion of a Phase I/II study of the anti-VISTA antibody KVA12123 in advanced

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sionna Gets CF Compounds AbbVie License

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. In this edition of Deal Watch, we highl

It’s understandable when a company running on fumes takes action to make its dwindling finances last while fundraising conditions are difficult. But when a company with a long cash runway implements l